According to a report in BusinessWeek , pharmaceutical major, Eli Lilly & Co. (NYSE:LLY) (FRA:LLY), has won its case in the U.S. Court of Appeals relating to patent protection for its compound patent, for Alimta (premetrexed). The drug curtails the tendency of cancerous cells to use folic acid and grow regardless of treatment with drugs. The ruling means that Alimta is protected in the U.S. up to January 2017. The report cites Robert A. Armitage, senior vice president and general counsel of Eli Lilly & Co. (NYSE:LLY) (FRA:LLY), who says: “We are pleased with today’s ruling from the Court of Appeals affirming the validity…
A Mixed Bag Of News For Eli Lilly’s Alimta Drug
HFA Staff
The post above is drafted by the collaboration of the Hedge Fund Alpha Team.